Threshold Pharmaceuticals, Inc (THLD): Opiniones

Más bonitas palabras.
Wall Street's Buy List

A ver si en breve, a parte de lo majete que puede ser ASCO, hay upgrades y cosucas de esas ;)

Sinceramente, creia que el valor se iba a calentar de cara a ASCO....

According to the analysts at Cowen, there's a $1.5 billion market staring Threshold in the face for its pancreatic cancer drug TH-302, and that's just in the U.S. Thus far, the data have been particularly encouraging, with nearly twice as many patients responding positively to the combination of TH-302 and Eli Lilly's Gemzar compared to those who took Gemzar alone.

Threshold's stock has pulled back 25% from its recent highs, but I thought the market drubbing was a little overwrought considering the prospects for success, so I rated it last month to beat the Street -- and so far the stock has advanced 9% compared to the S&P 500 losing 4.5% of its value. I expect Threshold to continue making gains like that, though perhaps not so large as the 450% jump in value it has realized since the start of the year.

CAPS member irishred1 is another who sees the promise and finds the pullback in price an opportunity, but the broader CAPS community remains somewhat hesitant to back it fully, possibly because more often than not early-stage biotechs lead to a lot of disappointment. Add Threshold Pharmaceuticals to your watchlist to see how solid of an investment it turns out to be.

Wall Street Loves These Stocks. Should You?

Cerro justo en 6,94!!! jajjajaj

Clavadita clavadita. Hoy a por los 7,09 - 7,10

El volumen es una "cacafuti", así que cualquier fondo con ganas la tumba o la levanta.
Yo particularmente no la veo muy caliente de cara a ASCO, así que después de ASCO me pensaría descansar una temporada. Enola además advirtio que en junio sería un buen momento para salir el que quiera.

Saludos y suerte

Bueno, ya le he echado un rato, a ver que os parece:

1.- La media movil a 50 acaba de ser perforada, así que si con ganas esta tarde la dejamos atras, tendriamos una muy buena señal. El 16 de mayo cuando se toco la media a 50, los cortos se pusieron casi al 60% del volumen, y normal que bajara, sobre todo teniendo en cuenta que no habia noticias.

2.- Ahora un 30% (aprox) del volumen son posiciones cortas, así que más o menos neutro. Quizá más bueno que malo.

Hay que estar atentos porque si despega, lo hará entre hoy y mañana. Si lo de ASCO gusta, subira más y pienso que nos estabilizaremos en torno a 8, y si no gusta tanto pues será un buen momento para hacer caja y esperar un momento para entrar.

Encarando ASCO

Acabo de recibirlo en el correo:

Threshold Pharmaceuticals Announces Presentation and Webcast at Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 05/30/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Chief Executive Officer of Threshold, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Wednesday, June 6, at 4:30 p.m. Eastern time in New York City.

A live webcast of the presentation will be available under Webcasts in the Investors section of www.thresholdpharm.com. A replay of the presentation will be archived on the site for 30 days.

About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, Threshold is building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit www.thresholdpharm.com.

Contact:
Joel A. Fernandes
Threshold Pharmaceuticals, Inc.
650.474.8273
Email Contact
Source: Threshold Pharmaceuticals

7,27 0,33(4.76%) 4:33PM GMT+02:00 - Precio en tiempo real Nasdaq